Loading...
XLON
CRW
Market cap491mUSD
Oct 09, Last price  
1,100.00GBP
1D
1.66%
1Q
-3.34%
Jan 2017
-16.98%
IPO
671.93%
Name

Craneware PLC

Chart & performance

D1W1MN
XLON:CRW chart
P/E
25.19
P/S
2.41
EPS
0.58
Div yield, %
2.95%
Shrs. gr., 5y
5.32%
Rev. gr., 5y
22.26%
Revenues
206m
+0.40%
15,110,70318,676,00022,993,00028,397,00038,124,00041,067,00041,452,00042,574,00044,817,00049,846,00057,796,00067,067,00071,401,00071,492,00075,578,000165,544,000174,018,000189,268,000205,657,000206,472,008
Net income
20m
+0.60%
1,216,2423,289,0004,448,0005,525,0006,015,0008,893,0008,296,0008,610,0009,388,00010,575,00013,525,00015,797,00014,985,00016,836,00012,905,0009,409,0009,232,00011,703,00019,663,00019,781,245
CFO
43m
-28.65%
987,4443,492,0007,176,0006,718,0008,494,0009,286,0006,617,0008,109,00019,582,00015,422,00017,852,00029,988,00013,463,00020,670,00023,537,00026,964,00098,748,00041,862,00059,898,00042,737,394
Dividend
Dec 03, 202617 GBP/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Craneware plc, alongside its various subsidiaries, is dedicated to developing, licensing, and providing ongoing support for specialized software solutions within the United States healthcare industry. The company's comprehensive suite of products addresses a wide range of operational and financial needs. For revenue cycle and financial management, Craneware offers Trisus pricing transparency software, designed to clarify pricing information, along with Trisus Pricing Analyzer to automate and simplify price modeling. Its Trisus Chargemaster provides automated management of chargemaster data, while InSight Audit assists government and commercial payors with audit processes. Additionally, InSight Denials facilitates the analysis, tracking, and reporting of claims denial data, and Trisus Claims Informatics offers retrospective analytical insights to identify charge capture risks. In the realm of clinical operations and supply chain, solutions include InSight Medical Necessity, which helps U.S. payors determine medical necessity; Trisus Supply, aimed at enhancing reimbursement for medical supplies; and Trisus Healthcare Intelligence, delivering patient-level insights into resource consumption. The portfolio also extends to Trisus Medication Analytic and Trisus Supplies Assistant solutions. Craneware also features a specialized line of pharmacy and drug tracking software. This includes Sentinel for drug tracking, Sentrex (a SaaS platform enabling covered entities to expand medication access), Sentrex 330, a Referral Verification System, and Sentry Core, which streamlines the complexities of pharmacy procurement, utilization, and compliance. Beyond its software offerings, Craneware provides professional and appeal services. The company was founded in 1999 and is headquartered in Edinburgh, United Kingdom.

Key people

Non-Executive Chairman of the Board · since 2020
Keith Neilson
Chief Executive Officer, Co-Founder, Executive Director · since 1999
Craig Preston
Chief Financial Officer, Company Secretary, Executive Director · since 2008
Isabel Urquhart
Chief People Officer, Executive Director · since 2022
Jill Goldsmith
Company Secretary · since 2025
Alistair Erskine
Senior Non-Executive Independent Director · since 2025
Anne Mccune
Non-Executive Independent Director · since 2022
Tamra Minnier
Non-Executive Independent Director · since 2024
Susan Nelson
Non-Executive Independent Director · since 2025
IPO date
Sep 13, 2007
Employees
724
Domiciled in
GB
Incorporated in
GB
Headquarters & legal address
Tanfield House
1 Tanfield
Edinburgh EH3 5DA
GB
Previous name
CRANEWARE LIMITED

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2026‑062025‑062024‑062023‑062022‑062021‑062020‑062019‑062018‑062017‑06
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT